Alterity Therapeutics Ltd. · ASX:ATH
Alterity Therapeutics — Prana Biotechnology — Shareholder Meeting (December 2012)
13 slides from Alterity Therapeutics's shareholder meeting presentation, Dec 12, 2012
Slide 1: Prana Biotechnology 2012 Highlights – Annual General Meeting
1 PRANA BIOTECHNOLOGY 2012 Highlights Annual General Meeting 12 December, 2012
Slide 2: Safe Harbour
2 Safe Harbour This presentation may contain some statements that may be considered “Forward-Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward-looking statement relating to financial projections or other statements relating to the Company’s plans, objectives, expec
Slide 3: 2012 – Key Achievements
2012 – Key Achievements • Opened IND through the FDA in the USA • Commenced IMAGINE Alzheimer’s disease trial with PBT2 • Commenced Reach2HD Huntington’s disease trial with PBT2 • Completed in-vitro toxicology of PBT434 funded by the Michael J Fox Foundation • Collaborated with US National Cancer In
Slide 4: Key Clinical Asset: PBT2
4 Key Clinical Asset: PBT2 • PBT2 is Prana’s most advanced neuroprotective drug candidate, in development for both Alzheimer’s Disease and Huntington’s Disease. • PBT2 has a differentiated and unique mechanism of action. • PBT2 has already been shown to improve cognition in Alzheimer’s patients, par
Slide 5: Alzheimer's – Memory is just a part of the disease
5 Alzheimer’s – Memory is just a part of the disease • Executive Function (EF) is an • Memory is the process of storing and integrated set of cognitive abilities, recalling information. To form long including thinking flexibility, term memories the brain needs concept formation, self-monitoring, acc
Slide 6: PBT2 improves Executive Function
6 PBT2 improves Executive Function p = 0.042 0.35 250mg n=27 Memory and executive function 0.3 50mg are both affected in Alzheimer’s n=19 0.25 0.2 Executive function is the main cognitive deficit in Huntington’s 0.15 placebo 0.1 n=28 0.05 Executive function: The overarching control of cognitive proc
Slide 7: Problems begin many years before full dementia
Problems begin many years before full dementia EF loss would appear as: Depression, apathy and Personality Change Memory Symptoms Dementia Functional Impairment Executive Dysfunction 3 Years AGE
Slide 8: The Disease develops well before dementia appears
The Disease develops well before dementia appears Clinical Changes (Memory) Normal At Risk Dementia Prodromal Dementia Disease
Slide 9: The Disease develops well before dementia appears
The Disease develops well before dementia appears Current Drug Clinical Changes (Memory) Rx Target memory Normal At Risk Dementia Prodromal Dementia Disease
Slide 10: The Disease develops well before dementia appears
The Disease develops well before dementia appears Current Drug Clinical Changes (Executive Function) Rx Target memory PBT2 Rx Target EF and memory Normal At Risk Dementia Prodromal Dementia Disease
Slide 11: Alzheimer's: Phase II IMAGINE Trial
11 Alzheimer’s: Phase II IMAGINE Trial • Double blind placebo controlled study • 40 early AD patients. • 12 months treatment period. • Measures effect of PBT2 on: • distribution of amyloid plaques in the brains of AD patients using PIB Imaging • brain volume using MRI • cognition • energy utilisatio
Slide 12: Huntington's Disease Phase II Reach2HD trial
12 Huntington’s Disease Phase II Reach2HD trial • Double blind placebo controlled study • 100 patients (approx) • 6 months treatment period • Safety and tolerability • Efficacy: cognition/motor/behavioural/psychiatric • 88% of target enrollment achieved • Enrollment completion Jan 2013 • Trial compl
Slide 13: Prana Asset Pipeline
13 Prana Asset Pipeline Preclinical Phase I Phase IIa Phase IIb Discovery Chemistry Screening Toxicology Clinical Clinical Clinical PBT2 Alzheimer’s Disease PBT2 Huntington’s Disease PBT434 Parkinson’s Disease (funded by Michael J Fox Foundation) PBT519 Brain Cancer 900+ MPAC Library
Prana Biotechnology — Shareholder Meeting (December 2012) on 6ix